Targeting DNA Repair in Cancer: Beyond PARP Inhibitors.

ABSTRACT: Germline aberrations in critical DNA-repair and DNA damage-response (DDR) genes cause cancer predisposition, whereas various tumors harbor somatic mutations causing defective DDR/DNA repair. The concept of synthetic lethality can be exploited in such malignancies, as exemplified by approval of poly(ADP-ribose) polymerase inhibitors for treating BRCA1/2-mutated ovarian cancers. Herein, we detail how cellular DDR processes engage various proteins that sense DNA damage, initiate signaling pathways to promote cell-cycle checkpoint activation, trigger apoptosis, and coordinate DNA repair. We focus on novel therapeutic strategies targeting promising DDR targets and discuss challenges of patient selection and the development of rational drug combinations.

Significance

Various inhibitors of

SUBMITTER: Brown JS 

PROVIDER: S-EPMC5300099 | biostudies-literature | 2017 Jan

REPOSITORIES: biostudies-literature